{
    "clinical_study": {
        "@rank": "94060", 
        "arm_group": {
            "arm_group_label": "venlafaxine ER", 
            "arm_group_type": "Other", 
            "description": "venlafaxine ER (extended-release) 75 mg once"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine whether a significant and predictable change in\n      bioavailability of extended-release venlafaxine occurs following Roux-en-Y gastric bypass."
        }, 
        "brief_title": "Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels", 
        "condition": [
            "Bariatric Surgery", 
            "Gastric Bypass", 
            "Roux-en-Y Gastric Bypass"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        - Approved to undergo Roux-en-Y gastric bypass surgery (cost of surgery is NOT included in\n        the study)\n\n        Exclusion criteria:\n\n          -  Pregnant\n\n          -  Allergy to venlafaxine or desvenlafaxine\n\n          -  Psychiatric hospitalization within the prior 12 months\n\n          -  Active professional treatment for recent substance abuse within 12 months of\n             abstinence\n\n          -  Ongoing psychologic issues, such as personality disorders, difficulties as a trauma\n             survivor, or difficulties with depression unless a stable, documented course of\n             treatment by a licensed mental health professional is available\n\n          -  Current use of any of the following medications/supplements:  5-hydroxytryptophan,\n             almotriptan, amitriptyline, amoxapine, amoxicillin-clavulanate,\n             amphetamine-dextroamphetamine, atazanavir, bupropion, cinacalcet, citalopram,\n             clarithromycin, clomipramine, desipramine, desvenlafaxine, dextroamphetamine,\n             dextromethorphan, doxepin, duloxetine, eletriptan, entacapone, escitalopram,\n             fluoxetine, fluvoxamine, frovatriptan, haloperidol, imipramine, isocarboxazid,\n             itraconazole, jujube seed extract, linezolid, maprotiline, methylene blue,\n             metoclopramide, metoprolol, milnacipran, mirtazapine, naratriptan, nefazodone,\n             nelfinavir, nortriptyline, paroxetine, phenelzine, procarbazine, protriptyline,\n             quinidine, rasagiline, ritonavir, rizatriptan, saquinavir, selegiline, sertraline,\n             St. John's wort, sumatriptan, tapentadol, terbinafine, toremifene, tramadol,\n             tranylcypromine, trazodone, trifluoperazine, trimipramine, tryptophan, L-tryptophan,\n             venlafaxine, vilazodone, zolmitriptan"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01867255", 
            "org_study_id": "12-005860"
        }, 
        "intervention": {
            "arm_group_label": "venlafaxine ER", 
            "description": "A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.", 
            "intervention_name": "venlafaxine ER (extended-release) 75 mg", 
            "intervention_type": "Drug", 
            "other_name": "Effexor XR 75 mg"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antidepressive Agents", 
                "Venlafaxine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "venlafaxine", 
            "Effexor", 
            "antidepressive agent"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "krieger.carrie@mayo.edu", 
                "last_name": "Carrie A Krieger, PharmD", 
                "phone": "507-266-5311"
            }, 
            "contact_backup": {
                "email": "cunningham.julie2@mayo.edu", 
                "last_name": "Julie A Krieger, PharmD", 
                "phone": "507-255-5866"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "investigator": [
                {
                    "last_name": "Julie L Cunningham, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Kristin J Somers, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Michael G Sarr, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd A Kellogg, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Karen Grothe, PhD, LP", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kathryn M Schak, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kyle R Cedermark, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Joel M Reid, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Matthew M Clark, PhD, LP", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Maria L Collazo-Clavell, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass", 
        "overall_contact": {
            "email": "krieger.carrie@mayo.edu", 
            "last_name": "Carrie A Krieger, PharmD", 
            "phone": "507-266-5311"
        }, 
        "overall_contact_backup": {
            "email": "cunningham.julie2@mayo.edu", 
            "last_name": "Julie L Cunningham, PharmD", 
            "phone": "507-255-5866"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Carrie Krieger, PharmD, RPh", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "This study will measure and compare venlafaxine and desvenlafaxine levels in participants before, and again 3 to 4 months after, gastric bypass surgery.", 
            "measure": "Venlafaxine levels pre- and post-gastric bypass", 
            "safety_issue": "No", 
            "time_frame": "3 to 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01867255"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Carrie A. Krieger", 
            "investigator_title": "PharmD, BCACP", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}